Meropenem Navamedic: Uses, Dosage & Side Effects
A broad-spectrum carbapenem antibiotic for the treatment of severe bacterial infections administered intravenously in hospital settings
Meropenem Navamedic is a broad-spectrum carbapenem antibiotic administered intravenously for the treatment of severe bacterial infections. It belongs to the beta-lactam class of antibiotics and is effective against a wide range of gram-positive, gram-negative, and anaerobic bacteria, including many organisms resistant to other antibiotic classes. Meropenem is used in hospital settings to treat complicated intra-abdominal infections, bacterial meningitis, hospital-acquired pneumonia, complicated skin and soft tissue infections, complicated urinary tract infections, and infections in patients with febrile neutropenia. It is classified by the World Health Organization as a critically important antimicrobial and is listed on the WHO Model List of Essential Medicines.
Quick Facts: Meropenem Navamedic
Key Takeaways
- Meropenem Navamedic is a carbapenem antibiotic with an exceptionally broad antibacterial spectrum, effective against gram-positive, gram-negative, and anaerobic bacteria, including many multidrug-resistant organisms such as ESBL-producing Enterobacterales.
- It is administered intravenously in hospital settings and is indicated for severe infections including bacterial meningitis, complicated intra-abdominal infections, hospital-acquired pneumonia, and febrile neutropenia in cancer patients.
- Meropenem has a critical drug interaction with valproic acid (valproate), reducing valproate blood levels by 60–100%, which can lead to loss of seizure control. Concurrent use should be avoided.
- The WHO classifies carbapenems in the “Watch” group of antibiotics, emphasizing the importance of antimicrobial stewardship to preserve their effectiveness against resistant organisms.
- Common side effects include diarrhea, nausea, vomiting, and injection site reactions; serious but rare adverse effects include Clostridioides difficile-associated diarrhea, seizures, and severe hypersensitivity reactions.
What Is Meropenem Navamedic and What Is It Used For?
Meropenem Navamedic contains the active substance meropenem, a synthetic carbapenem antibiotic belonging to the beta-lactam class. Carbapenems are considered among the most potent and broad-spectrum antibiotics available in clinical medicine, and they play a critical role in the treatment of severe and life-threatening infections, particularly those caused by multidrug-resistant bacteria. Meropenem was first approved for clinical use in the 1990s and has since become one of the most widely used carbapenems worldwide, included on the World Health Organization (WHO) Model List of Essential Medicines.
The mechanism of action of meropenem is fundamentally similar to that of other beta-lactam antibiotics, but with important structural differences that give it its broad spectrum and stability. Like all beta-lactams, meropenem exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes (transpeptidases, carboxypeptidases, and endopeptidases) that catalyze the cross-linking of peptidoglycan strands, which is the final step in bacterial cell wall biosynthesis. By binding to and inhibiting these enzymes, meropenem disrupts the structural integrity of the peptidoglycan layer, leading to osmotic instability, cell lysis, and ultimately bacterial death.
What distinguishes meropenem from narrower-spectrum beta-lactams such as penicillins and cephalosporins is its remarkable structural stability against bacterial beta-lactamases. Beta-lactamases are enzymes produced by bacteria that hydrolyze the beta-lactam ring, rendering the antibiotic inactive. Meropenem is stable against most clinically important beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), AmpC cephalosporinases, and many chromosomal beta-lactamases. This stability is conferred by the trans-1-methylcarbapenem ring structure and the 1-beta-methyl side chain, which sterically hinder access of most beta-lactamases to the beta-lactam ring. However, meropenem is susceptible to hydrolysis by certain carbapenemases, including metallo-beta-lactamases (MBLs such as NDM, VIM, and IMP), KPC-type serine carbapenemases, and OXA-48-like enzymes, which represent a growing global health concern.
Meropenem demonstrates bactericidal activity against an exceptionally broad range of clinically relevant pathogens. Its spectrum of activity includes gram-positive organisms such as Streptococcus pneumoniae, Streptococcus pyogenes, and methicillin-susceptible Staphylococcus aureus (MSSA); gram-negative organisms including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Neisseria meningitidis, Enterobacter species, Serratia marcescens, Citrobacter species, and Acinetobacter baumannii; and anaerobic bacteria such as Bacteroides fragilis, Prevotella species, and Clostridium species (excluding Clostridioides difficile). Notably, meropenem does not have reliable activity against methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecium, or Stenotrophomonas maltophilia.
Meropenem Navamedic is indicated for the treatment of the following infections in adults and children aged 3 months and older, when caused by susceptible bacteria:
- Complicated intra-abdominal infections: Peritonitis, appendicitis with complications, intra-abdominal abscess, and other polymicrobial abdominal infections requiring broad-spectrum coverage of gram-negative aerobes and anaerobes.
- Bacterial meningitis: Meropenem is one of the few beta-lactams that achieves therapeutically effective concentrations in the cerebrospinal fluid (CSF), making it suitable for treating meningitis caused by susceptible organisms including Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae.
- Hospital-acquired pneumonia, including ventilator-associated pneumonia (VAP): Meropenem provides coverage against the gram-negative pathogens commonly implicated in nosocomial respiratory infections, including Pseudomonas aeruginosa and ESBL-producing Enterobacterales.
- Complicated skin and soft tissue infections: Including necrotizing fasciitis, deep wound infections, and polymicrobial soft tissue infections.
- Complicated urinary tract infections: Including pyelonephritis with complications and urosepsis, particularly when caused by resistant organisms.
- Febrile neutropenia: Meropenem is used as empiric monotherapy in cancer patients with febrile neutropenia, providing broad-spectrum coverage during the critical period when the specific causative organism has not yet been identified.
Meropenem displays time-dependent bactericidal activity, meaning that the primary pharmacokinetic/pharmacodynamic (PK/PD) parameter that determines its efficacy is the percentage of the dosing interval during which the free (unbound) drug concentration remains above the minimum inhibitory concentration (MIC) of the pathogen, expressed as %fT>MIC. Studies have established that meropenem achieves optimal bactericidal activity when free drug concentrations exceed the MIC for approximately 40–50% of the dosing interval for most susceptible pathogens. This PK/PD relationship has important implications for dosing strategies, including the use of extended or continuous infusions in critically ill patients to maximize the time above MIC.
Meropenem should be used judiciously and in accordance with antimicrobial stewardship principles. The WHO classifies carbapenems in the “Watch” group of antibiotics, indicating that they should be used selectively as first- or second-choice treatment for a limited number of specific infections. Overuse of carbapenems drives the emergence of carbapenem-resistant organisms (CROs), which the WHO has classified as critical-priority pathogens. Always use the narrowest-spectrum antibiotic appropriate for the infection whenever possible.
What Should You Know Before Taking Meropenem Navamedic?
Contraindications
The primary contraindication to meropenem use is hypersensitivity (allergy) to meropenem, any other carbapenem antibiotic, or to any of the excipients in the formulation. Patients who have experienced anaphylaxis or other severe hypersensitivity reactions to any beta-lactam antibiotic (penicillins or cephalosporins) should also use meropenem with extreme caution, as cross-reactivity between beta-lactam classes is possible, although the rate of cross-reactivity between carbapenems and penicillins is estimated to be relatively low (approximately 1–3%).
Meropenem Navamedic powder for solution for injection/infusion contains sodium carbonate as an excipient. Each 1 g vial contains approximately 3.92 mmol (approximately 90 mg) of sodium. This should be taken into consideration for patients on a controlled sodium diet or those with conditions that require sodium restriction, such as congestive heart failure, renal impairment, or hypertension.
Warnings and Precautions
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibiotics, including meropenem. These reactions are more likely in patients with a history of sensitivity to multiple allergens. If a severe allergic reaction occurs, discontinue meropenem immediately and institute emergency treatment including epinephrine, corticosteroids, and airway management as clinically indicated.
Before starting meropenem treatment, the following considerations should be discussed with your healthcare provider:
- History of seizures or CNS disorders: Meropenem, like other carbapenems, has been associated with seizures and other central nervous system (CNS) adverse events. The risk is increased in patients with pre-existing CNS pathology (brain lesions, history of seizures), compromised renal function (which leads to drug accumulation), or when dosing exceeds the recommended maximum. In clinical trials, the incidence of seizures with meropenem was lower than with imipenem/cilastatin (another carbapenem), and meropenem is generally considered to have a more favorable CNS safety profile among carbapenems.
- Renal impairment: Meropenem is primarily eliminated by the kidneys. In patients with impaired renal function, dose reduction is necessary to prevent drug accumulation, which increases the risk of seizures and other adverse effects. Creatinine clearance should be measured or estimated, and the dose adjusted according to established guidelines.
- Hepatic function: Meropenem may cause transient elevations in liver enzymes (transaminases, alkaline phosphatase, bilirubin). Liver function should be monitored during treatment, particularly in patients with pre-existing hepatic disease. In rare cases, hepatic failure has been reported, predominantly in patients with serious underlying disease or receiving other hepatotoxic agents.
- Clostridioides difficile-associated diarrhea (CDAD): Like all antibiotics, meropenem can disrupt the normal intestinal flora, creating conditions for overgrowth of Clostridioides difficile, which can range from mild diarrhea to life-threatening pseudomembranous colitis. CDAD should be considered in all patients who develop diarrhea during or after antibiotic therapy. If CDAD is suspected or confirmed, meropenem should be discontinued and appropriate therapy initiated.
- Superinfection: Prolonged use of meropenem may result in overgrowth of non-susceptible organisms, including fungi. Regular clinical monitoring is essential, and if superinfection occurs, appropriate measures should be taken.
Children
Meropenem is approved for use in children aged 3 months and older at doses adjusted for body weight. In neonates (younger than 3 months), the safety and pharmacokinetics of meropenem are less well established, and use in this population requires specialist guidance. Clinical studies in pediatric patients have demonstrated a safety profile consistent with that observed in adults, with diarrhea and rash being the most commonly reported adverse effects in children.
Pregnancy and Breastfeeding
There are limited clinical data regarding the use of meropenem during pregnancy. Animal reproductive studies have not demonstrated teratogenic effects or adverse effects on fertility or postnatal development. However, in the absence of adequate controlled studies in pregnant women, meropenem should only be used during pregnancy when the potential benefit to the mother clearly outweighs the potential risk to the fetus. This is particularly relevant because meropenem is typically reserved for severe, life-threatening infections where the risk of not treating may itself be dangerous.
Meropenem has been detected in breast milk at very low concentrations. The effect on breastfed infants is not fully known, but the low oral bioavailability of meropenem suggests that systemic exposure in the infant would be minimal. Nevertheless, the decision to continue breastfeeding during meropenem treatment should be made in consultation with a specialist physician, weighing the benefits of breastfeeding against the theoretical risks to the infant, including potential effects on the infant’s gut microbiome.
Driving and Operating Machinery
No studies on the effects of meropenem on the ability to drive and use machines have been performed. However, headache, paraesthesia, and seizures have been reported with meropenem use. Patients who experience these or other CNS effects should avoid driving or operating machinery until the symptoms have resolved.
How Does Meropenem Navamedic Interact with Other Drugs?
While meropenem has a relatively favorable drug interaction profile compared to many other antibiotic classes, it does have several clinically significant interactions that healthcare providers must be aware of. Unlike macrolide or fluoroquinolone antibiotics, meropenem is not metabolized by cytochrome P450 (CYP) enzymes and is therefore not expected to inhibit or induce the metabolism of drugs that are CYP substrates. However, its primary interactions occur through other mechanisms, most notably effects on drug disposition and pharmacodynamic interactions.
| Interacting Drug | Mechanism | Clinical Effect | Severity |
|---|---|---|---|
| Valproic acid / Divalproex | Inhibition of valproate glucuronide hydrolysis; enhanced renal clearance | Reduces valproate levels by 60–100%; risk of seizures | Major – Avoid combination |
| Probenecid | Inhibits renal tubular secretion of meropenem | Increases meropenem AUC by ~55% and half-life | Moderate – Co-administration not recommended |
| Oral anticoagulants (warfarin) | Disruption of vitamin K-producing gut flora; possible effect on clotting factors | May increase INR and bleeding risk | Moderate – Monitor INR closely |
| Other nephrotoxic drugs | Additive renal toxicity risk | Increased risk of renal impairment; may affect meropenem clearance | Moderate – Monitor renal function |
| Live vaccines (e.g., BCG, typhoid) | Antibiotic may reduce efficacy of live bacterial vaccines | Potential reduction in vaccine immunogenicity | Minor – Avoid concurrent use if possible |
Major Interactions
The most clinically significant and well-documented drug interaction with meropenem involves valproic acid (sodium valproate, divalproex sodium). Multiple case reports, pharmacokinetic studies, and systematic reviews have consistently demonstrated that co-administration of meropenem with valproic acid leads to a dramatic reduction in serum valproate concentrations, typically by 60–100%. This interaction occurs rapidly, often within 24–48 hours of starting meropenem, and can persist for several days after meropenem is discontinued.
The mechanism of this interaction is multifactorial. Meropenem inhibits the enzyme acylpeptide hydrolase, which is responsible for converting valproate glucuronide back to free valproate in the enterohepatic circulation. By blocking this enzymatic conversion, meropenem accelerates the irreversible elimination of valproate glucuronide in the urine, effectively removing valproate from the body before it can be recycled. Additionally, meropenem may enhance the direct renal clearance of valproate and its metabolites.
The clinical consequence of this interaction is potentially catastrophic: patients with epilepsy who depend on valproate for seizure control may experience breakthrough seizures, including status epilepticus, within 1–2 days of starting meropenem. Importantly, increasing the dose of valproate does not reliably overcome this interaction, as the fundamental mechanism involves accelerated elimination rather than reduced absorption. Therefore, the concurrent use of meropenem and valproic acid is generally contraindicated, and alternative antibiotics (for the infection) or alternative anticonvulsants (for seizure control) should be used whenever possible.
Minor and Moderate Interactions
Probenecid competes with meropenem for active renal tubular secretion, resulting in increased plasma concentrations of meropenem (approximately 55% increase in AUC) and a prolonged half-life. While this interaction was historically used with some beta-lactams to deliberately prolong their duration of action, co-administration of probenecid with meropenem is not recommended due to the risk of toxicity and because the increased exposure does not provide meaningful clinical benefit given that meropenem already achieves adequate therapeutic levels with standard dosing.
Oral anticoagulants including warfarin may demonstrate enhanced anticoagulant effects when used concomitantly with meropenem. This is a class effect of antibiotics that disrupt the vitamin K-producing intestinal flora, potentially reducing the synthesis of vitamin K-dependent clotting factors. Patients receiving warfarin or other vitamin K antagonists should have their International Normalized Ratio (INR) monitored more frequently during and after meropenem therapy, with dose adjustments as necessary.
If you are taking valproic acid (valproate) for epilepsy, bipolar disorder, or migraine prevention, inform your doctor immediately before meropenem is prescribed. This interaction is severe and unpredictable. Alternative antibiotics or alternative seizure medications should be considered. If meropenem must be used, valproate levels and seizure control should be monitored extremely closely, and supplemental anticonvulsant therapy may be necessary.
What Is the Correct Dosage of Meropenem Navamedic?
Meropenem Navamedic is always administered under medical supervision in a hospital or clinical setting. The powder must be reconstituted with a compatible sterile diluent (water for injections, sodium chloride 0.9%, or glucose 5%) before administration. Meropenem can be given as an intravenous bolus injection over approximately 5 minutes or as an intravenous infusion over 15 to 30 minutes. In critically ill patients, extended infusions of 3–4 hours may be used to optimize pharmacokinetic/pharmacodynamic parameters, particularly for pathogens with higher MIC values.
Adults
| Indication | Dose | Frequency | Infusion Duration |
|---|---|---|---|
| Complicated intra-abdominal infections | 500 mg – 1 g | Every 8 hours | 15–30 min (or 5 min bolus) |
| Hospital-acquired / ventilator-associated pneumonia | 1 g – 2 g | Every 8 hours | 15–30 min (or extended 3–4 h) |
| Bacterial meningitis | 2 g | Every 8 hours | 15–30 min |
| Complicated skin and soft tissue infections | 500 mg – 1 g | Every 8 hours | 15–30 min (or 5 min bolus) |
| Complicated urinary tract infections | 500 mg – 1 g | Every 8 hours | 15–30 min (or 5 min bolus) |
| Febrile neutropenia (empiric) | 1 g – 2 g | Every 8 hours | 15–30 min |
The maximum recommended dose of meropenem in adults is 2 g every 8 hours (6 g per day). The duration of treatment depends on the type and severity of infection and the clinical response. For most indications, treatment courses typically range from 5 to 14 days. In bacterial meningitis, the standard treatment duration is 10 to 14 days. Treatment should be reassessed regularly, and de-escalation to narrower-spectrum antibiotics should be considered once culture and susceptibility results are available, in accordance with antimicrobial stewardship principles.
Children (3 Months and Older)
Pediatric dosing of meropenem is based on body weight, with the following general recommendations:
| Indication | Dose | Frequency | Maximum |
|---|---|---|---|
| Most infections | 10–20 mg/kg | Every 8 hours | Max 1 g per dose |
| Bacterial meningitis / Febrile neutropenia | 40 mg/kg | Every 8 hours | Max 2 g per dose |
Children weighing over 50 kg should receive adult doses. For neonates and infants younger than 3 months, dosing has not been fully established and requires specialist guidance, typically using weight-based dosing with extended dosing intervals to account for the immature renal function in this age group.
Elderly Patients
No dose adjustment is required for elderly patients with normal renal function. However, since renal function naturally declines with age, creatinine clearance should be assessed in elderly patients, and the dose should be adjusted if renal impairment is identified. Elderly patients may also be more susceptible to certain adverse effects, including gastrointestinal disturbances and CNS effects.
Renal Impairment
Meropenem is eliminated primarily by the kidneys, and dose reduction is essential in patients with impaired renal function to prevent drug accumulation and associated toxicity. The following dose adjustments are recommended based on creatinine clearance (CrCl):
| Creatinine Clearance | Dose | Frequency |
|---|---|---|
| > 50 mL/min | Standard dose | Every 8 hours |
| 26–50 mL/min | Standard dose | Every 12 hours |
| 10–25 mL/min | 50% of standard dose | Every 12 hours |
| < 10 mL/min | 50% of standard dose | Every 24 hours |
In patients receiving hemodialysis, meropenem and its metabolites are removed by the dialysis process. A supplemental dose of meropenem is recommended after each dialysis session. Patients receiving continuous renal replacement therapy (CRRT) require individualized dosing based on the specific modality and flow rates, guided by therapeutic drug monitoring where available.
Missed Dose
Since meropenem is administered in a hospital setting by healthcare professionals, the risk of missed doses is managed by clinical staff. If a dose is inadvertently missed, it should be administered as soon as possible, and the regular dosing schedule should be resumed. Do not double the dose to compensate for a missed dose. Consistent timing of doses is important to maintain therapeutic drug levels and optimize the time-dependent bactericidal activity of meropenem.
Overdose
Overdose with meropenem may occur, particularly in patients with renal impairment who do not receive appropriate dose adjustments. Symptoms of overdose may include nausea, vomiting, diarrhea, and neurological symptoms including seizures, confusion, and tremor. There is no specific antidote for meropenem overdose. Treatment is supportive, with attention to maintaining adequate hydration and renal function. Meropenem is removed by hemodialysis, which may be considered in cases of severe overdose or renal failure.
What Are the Side Effects of Meropenem Navamedic?
Like all antibiotics, meropenem can cause side effects, although not everyone will experience them. The side effect profile of meropenem has been well characterized through extensive clinical trials involving thousands of patients and decades of post-marketing surveillance. Overall, meropenem is considered to have a favorable safety profile for a broad-spectrum antibiotic, with most adverse effects being mild to moderate and transient.
The following side effects are organized by frequency according to standard medical conventions used by regulatory agencies (EMA, FDA):
Very Common (affects more than 1 in 10 patients)
Frequency: > 1/10
- Thrombocytosis (increased platelet count)
Common (affects 1 to 10 in 100 patients)
Frequency: 1/100 to 1/10
- Diarrhea
- Nausea
- Vomiting
- Headache
- Rash (including maculopapular rash)
- Pruritus (itching)
- Injection site reactions (inflammation, pain, thrombophlebitis)
- Elevated liver enzymes (ALT, AST, alkaline phosphatase, LDH)
- Elevated bilirubin
- Eosinophilia (increased eosinophil count)
- Thrombocytopenia (decreased platelet count)
- Increased blood creatinine
Uncommon (affects 1 to 10 in 1,000 patients)
Frequency: 1/1,000 to 1/100
- Oral and vaginal candidiasis (thrush)
- Abdominal pain
- Paraesthesia (tingling, numbness)
- Urticaria (hives)
- Leukopenia (decreased white blood cell count)
- Neutropenia (decreased neutrophil count)
- Positive direct Coombs test
Rare (affects 1 to 10 in 10,000 patients)
Frequency: 1/10,000 to 1/1,000
- Seizures (convulsions)
- Clostridioides difficile-associated diarrhea (pseudomembranous colitis)
- Anaphylaxis (severe allergic reaction)
- Angioedema (swelling of face, lips, tongue, throat)
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
- Hemolytic anemia
- Agranulocytosis (very low white blood cell count)
- Hepatic failure
Not Known (frequency cannot be estimated from available data)
Frequency: Not known
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Acute generalized exanthematous pustulosis (AGEP)
The gastrointestinal side effects of meropenem (diarrhea, nausea, vomiting) are among the most commonly reported and are a direct consequence of the drug’s broad-spectrum antibacterial activity, which disrupts the normal intestinal microbiome. These effects are usually mild to moderate and self-limiting, resolving after the completion of therapy. However, severe or persistent diarrhea should always be evaluated for Clostridioides difficile infection, which can occur during or up to several weeks after antibiotic treatment.
Injection site reactions, including thrombophlebitis (inflammation of the vein at the injection site), are commonly associated with intravenous antibiotic administration. These can be minimized by using appropriate infusion techniques, rotating injection sites, and ensuring proper dilution of the reconstituted solution.
The neurological side effects of meropenem, particularly seizures, deserve special attention. While meropenem is generally considered to have a lower seizure risk compared to imipenem/cilastatin (another carbapenem), seizures have been reported, particularly in patients with pre-existing CNS disorders, renal impairment (leading to drug accumulation), or at doses exceeding the recommended maximum. If seizures occur during meropenem therapy, the drug should be discontinued or the dose reduced, and appropriate anticonvulsant therapy should be initiated.
Contact your healthcare team immediately if you experience: signs of a severe allergic reaction (difficulty breathing, swelling of the face, lips, tongue, or throat, severe skin rash with blistering); severe or bloody diarrhea; seizures or convulsions; yellowing of the skin or eyes (jaundice); or dark urine. These may indicate serious adverse reactions requiring urgent medical intervention.
How Should You Store Meropenem Navamedic?
Meropenem Navamedic, as a powder for solution for injection/infusion, is a hospital-administered medication whose storage and preparation are typically managed by trained pharmacy or nursing personnel. Understanding the storage requirements is important for ensuring the stability, efficacy, and safety of the reconstituted product.
Unopened vials: Store below 30°C. Keep the vial in the outer carton to protect from light. Do not freeze the unreconstituted powder. Meropenem Navamedic powder for injection/infusion has a defined shelf life as indicated on the packaging, and vials should not be used after the expiration date printed on the label and carton.
After reconstitution: Once reconstituted with water for injections for bolus injection, the solution should be used immediately. From a microbiological point of view, reconstituted solutions should be used within the validated time frame specified in the product information. When diluted in sodium chloride 0.9% or glucose 5% for intravenous infusion, chemical and physical stability data support use within specific time periods depending on the diluent and storage conditions. However, from a microbiological safety standpoint, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
Visual inspection: The reconstituted solution should be a clear, colorless to pale yellow solution. Do not use the solution if it is cloudy, contains visible particles, or appears discolored. Any unused solution should be discarded in accordance with local hospital protocols for pharmaceutical waste.
As with all medicines, keep Meropenem Navamedic out of the sight and reach of children. Do not dispose of unused medication via household waste or wastewater. Follow local hospital and regulatory guidelines for the safe disposal of pharmaceutical products.
What Does Meropenem Navamedic Contain?
Understanding the composition of Meropenem Navamedic is important for healthcare professionals managing patients with specific dietary restrictions, allergies, or conditions that require careful monitoring of electrolyte intake.
Active substance: Meropenem (as meropenem trihydrate). Each vial contains meropenem trihydrate equivalent to 1 g (1,000 mg) of meropenem. Meropenem trihydrate is a white to pale yellow crystalline powder with the molecular formula C17H25N3O5S·3H2O and a molecular weight of 437.51 g/mol (trihydrate form) or 383.46 g/mol (anhydrous form). Meropenem belongs to the carbapenem subclass of beta-lactam antibiotics and contains a carbapenem ring fused to a five-membered ring with a trans-hydroxyethyl substituent.
Excipient: Sodium carbonate (anhydrous). This inorganic salt serves as a buffering agent to maintain the appropriate pH of the reconstituted solution. When dissolved, the reconstituted solution has a pH of approximately 7.3 to 8.3, making it suitable for intravenous administration.
Sodium content: Each 1 g vial of Meropenem Navamedic contains approximately 3.92 mmol (approximately 90 mg) of sodium from the sodium carbonate excipient. This is equivalent to approximately 4.5% of the WHO-recommended maximum daily intake of 2 g of sodium for an adult per single dose. For patients receiving the maximum dose of 2 g every 8 hours (three vials per day), the total sodium intake from meropenem alone would be approximately 270 mg per day. This should be considered when managing patients on sodium-restricted diets, particularly those with heart failure, hepatic cirrhosis with ascites, or renal impairment.
What the product looks like: Meropenem Navamedic is a white to pale yellow powder supplied in glass vials sealed with a rubber stopper and aluminum overseal with a flip-off cap. The powder is presented as a single-dose vial. After reconstitution with water for injections, sodium chloride 0.9%, or glucose 5%, the resulting solution should be clear and colorless to pale yellow.
Frequently Asked Questions About Meropenem Navamedic
Meropenem Navamedic is a broad-spectrum carbapenem antibiotic used to treat severe bacterial infections in hospitals. It is indicated for complicated intra-abdominal infections, bacterial meningitis, complicated skin and soft tissue infections, complicated urinary tract infections, hospital-acquired pneumonia (including ventilator-associated pneumonia), and infections during febrile neutropenia in cancer patients. It works by inhibiting bacterial cell wall synthesis and is effective against a very wide range of gram-positive, gram-negative, and anaerobic bacteria.
Meropenem Navamedic is given intravenously (into a vein) by a healthcare professional in a hospital setting. The powder must be dissolved (reconstituted) with a sterile liquid before use. It can be given as a quick injection over about 5 minutes or as a drip (infusion) over 15 to 30 minutes. In some critically ill patients, the infusion may be extended to 3–4 hours to optimize drug levels in the body. It is not available as a tablet or oral liquid.
Meropenem is classified as a carbapenem, which is among the broadest-spectrum antibiotic classes available. The WHO places carbapenems in the “Watch” group, meaning their use should be carefully controlled to preserve their effectiveness. Overuse of carbapenems promotes the emergence of carbapenem-resistant organisms, which are extremely difficult to treat and represent one of the greatest threats in antimicrobial resistance globally. Therefore, meropenem is typically reserved for severe infections where narrower-spectrum antibiotics are insufficient or when resistant organisms are suspected or confirmed.
No, concurrent use of meropenem and valproic acid is generally contraindicated. Meropenem dramatically reduces blood levels of valproic acid (by 60–100%), which can lead to loss of seizure control, including potentially life-threatening status epilepticus. This interaction occurs rapidly (within 1–2 days) and cannot be reliably managed by increasing the valproate dose. If you are taking valproic acid, your doctor should consider alternative antibiotics or alternative seizure medications.
The most common side effects include diarrhea, nausea, vomiting, injection site reactions (pain, inflammation, thrombophlebitis), headache, and rash. Laboratory changes such as elevated liver enzymes and changes in blood cell counts (thrombocytosis, eosinophilia) are also common. Most side effects are mild to moderate and resolve after treatment is completed. Serious but rare side effects include Clostridioides difficile-associated diarrhea, seizures, and severe allergic reactions.
There are limited data on meropenem use in pregnant women. Animal studies have not shown harmful effects on reproduction or fetal development. However, as a precaution, meropenem should only be used during pregnancy when the potential benefit to the mother clearly outweighs the potential risk to the fetus. Since meropenem is reserved for severe, life-threatening infections, the clinical situation often requires its use regardless. The decision should always be made by a specialist physician experienced in managing infections in pregnancy.
References
- European Medicines Agency (EMA). Meropenem – Summary of Product Characteristics. Updated 2025. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). MERREM I.V. (meropenem for injection) – Full Prescribing Information. Revised 2024.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: World Health Organization; 2023.
- World Health Organization. WHO AWaRe Classification of Antibiotics for Evaluation and Monitoring of Use, 2023. Geneva: World Health Organization; 2023.
- Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133–164.
- Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267–1284.
- Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs. 2008;68(6):803–838. doi:10.2165/00003495-200868060-00006
- Lunde CS, Hartouni SR, Janc JW, et al. Meropenem pharmacokinetics and pharmacodynamics: a review. Expert Rev Anti Infect Ther. 2023;21(3):267–281.
- Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev. 2007;39(4):647–657. doi:10.1080/03602530701690341
- Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20(Suppl 1):1–55.
Medical Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Infectious Disease and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following WHO, EMA, FDA, and IDSA guidelines
Evidence Standard
Level 1A – Based on systematic reviews, meta-analyses, and randomized controlled trials using the GRADE framework
Independence
No pharmaceutical funding. All content is editorially independent with no commercial conflicts of interest.
All medical information on iMedic is reviewed according to international clinical guidelines and best-practice recommendations. Our editorial process follows the principles of evidence-based medicine, with all clinical claims supported by peer-reviewed sources. Content is regularly updated to reflect the latest scientific evidence and regulatory guidance.